CIK 1395064
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q2. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 96.95% | 6 |
| Commercial Services & Supplies | 2.92% | 1 |
| Life Sciences Tools & Services | 0.13% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | OVID | Ovid Therapeutics Inc. | Health Care | 59.82% |
| 2 | EQ | Equillium, Inc. | Health Care | 15.94% |
| 3 | XLO | Xilio Therapeutics, Inc. | Health Care | 7.59% |
| 4 | STTK | Shattuck Labs, Inc. | Health Care | 7.53% |
| 5 | LYEL | Lyell Immunopharma, Inc. | Health Care | 5.45% |
| 6 | AMWL | American Well Corp | Industrials | 2.92% |
| 7 | RANI | Rani Therapeutics Holdings, Inc. | Health Care | 0.62% |
| 8 | LAB | STANDARD BIOTOOLS INC. | Health Care | 0.13% |
8/8 names classified · sector 100.0% of weight · industry 100.0% · mkt cap 100.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 100.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/8 names) · unclassified 100.0%: OVID, EQ, XLO, STTK, LYEL, AMWL, RANI, LAB. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | OVIDOVID THERAPEUTICS INC | 7,531,996 | $10M | 59.8% | HOLD |
| 2 | EQEQUILLIUM INC | 1,824,977 | $3M | 15.9% | HOLD |
| 3 | XLOXILIO THERAPEUTICS INC | 1,475,121 | $1M | 7.6% | HOLD |
| 4 | STTKSHATTUCK LABS INC | 515,619 | $1M | 7.5% | HOLD |
| 5 | LYELLyell Immunopharma, Inc. | 54,887 | $891,365 | 5.4% | ADD 33% |
| 6 | AMWLAMERICAN WELL CORP | 77,733 | $478,061 | 2.9% | HOLD |
| 7 | RANIRANI THERAPEUTICS HLDGS INC | 203,190 | $101,554 | 0.6% | HOLD |
| 8 | LABSTANDARD BIOTOOLS INC | 16,515 | $21,470 | 0.1% | HOLD |
Where this firm's principals came from and which firms its alumni went on to found.
